Ewing Sarcoma

Moreover, these components are characterized by distinct molecular alterations from primary CNS tumors, without C19MC alterations for ETMRs, with an overrepresented SHH-subgroup for medulloblastomas, and with an epigenetic profile distinct from CNS counterparts in ovarian ependymomas. These data need to be confirmed before they can be incorporated into future patient personalized treatment.

Subsequent imaging revealed no evidence of metastatic disease, and re-excision showed no residual tumor. Primary superficial Ewing sarcoma is extremely rare, and this is only the second molecularly confirmed case of rectal origin.

This study highlights strong gene-environment interactions, frequent germline mutations, and the protective role of diet in gastric cancer risk. The findings emphasize the need for population-specific genetic screening, counselling, and preventive strategies tailored to Northeast India's unique populations.

Notably, 41 exhibited favorable oral pharmacokinetics and significant antitumor efficacy in MV4-11 xenograft models. Collectively, this work expands the chemical space of RBM39 degraders and supports their continued development as RNA splicing-targeted anticancer agents.

P=N/A, N=340, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting

Both diagnostic and therapeutic management should take place in specialized sarcoma centers. This article aims to provide an up-to-date overview of current diagnostic and therapeutic approaches in Ewing sarcoma.

While MAPK pathway inhibitors show limited efficacy in monotherapy, preclinical and clinical data suggest that their integration with existing treatment strategies may enhance therapeutic robustness, delay resistance and reduce recurrence. Targeting MAPK, in combination with other drugs that restrain CSC plasticity could represent a promising strategy to improve long-term outcomes in TNBC.

The patient remained disease-free 5 years after surgery. This case highlights the diagnostic importance of integrating histopathology, immunoprofiling, and molecular analysis in patients with rare salivary gland tumors and underscores the favorable outcomes of complete surgical resection for HCCC of the tongue.

The patient was promptly started on neoadjuvant chemotherapy (VAC + IE [vincristine, adriamycin, cyclophosphamide, ifosfamide, and etoposide]), which he tolerated well without significant adverse effects. Given the aggressive nature of renal EWS, a multimodal treatment approach involving chemotherapy followed by radical nephrectomy is essential for improving prognosis. This case sheds light on the importance of considering renal EWS in the differential diagnosis of renal masses and emphasizes the role of early intervention in enhancing survival outcomes.

This study aims to address whether simultaneously targeting CTH and mTOR could enhance therapeutic outcomes beyond those achieved by mTOR inhibition alone.CCOC lines were engineered with CTH knockout (KO) or treated with the CTH inhibitor Aviglycine hydrochloride (AVG; ABG-3168); mTOR was blocked with everolimus, a clinical stage mTOR inhibitor...In CTH-deficient models, the synergy was maintained; however, pharmacological inhibition of CTH with AVG did not produce additional effects, indicating dependence on CTH activity and supporting an on-target mechanism. Similar antiproliferative effects with combined treatment were observed in a CTH-expressing Ewing sarcoma (EwS) model.Together, these findings support biomarker-guided strategies and rational combination therapies that achieve dual targeting of mTOR and CTH, thereby disrupting protein translation and hypoxia adaptation in CCOC and other CTH-expressing cancers.

This single-center cohort from Türkiye confirms the key clinical features of FOP associated with both common and rare ACVR1 variants and expands the radiological findings with notable features such as pontine malformation. It also highlights scalp nodules as a potential early diagnostic clue, emphasizing the importance of early clinical recognition and timely molecular confirmation, while providing insights that may inform future therapeutic approaches.

Cases with available immunohistochemistry showed most EWS tumors (24/26, 92%) expressed a combination of CD99, FLI1, and ERG, while both SEF cases were positive for MUC4. Our results highlight the importance of molecular testing in providing an integrated diagnosis and are informative regarding the spectrum of renal neoplasia that harbor EWSR1 rearrangements, including EWS, DSRCT, SEF, and TLFRCC as these tumors can exhibit significant clinicopathologic heterogeneity.